Prophylactic platelet transfusions are routinely used following hematopoietic stem cell transplantation (HSCT) to reduce the risk of significant bleeding. Refractoriness to platelet transfusions (RPT) may be observed in 10-70% of patients receiving long-term blood component support. 1 Among immune causes of RPT, HLA antibodies can be found in up to 20-70% of patients receiving multiple platelet transfusions. 2, 3 The presence of such HLA alloimmunization leads to RPT in about a 30-50% of cases. 4 The proposed management of RPT is often unsatisfactory. Immunoadsorption (IA) plasmapheresis using a staphylococcal protein A column has shown some efficacy in the treatment of RPT in patients with hematologic malignancies or following HSCT. [5] [6] [7] We report a case of successful HSCT using protein A IA therapy as part of the conditioning regimen in a patient with RPT due to HLA antibodies.
A 14-year-old male presented in 1991 with aplastic anemia associated with paroxysmal nocturnal hemoglobinuria. The patient was maintained on transfusion support until July 1998, when he received an unrelated matched HSCT. By that time, he had received over 200 washed red cell concentrates and 300 pooled whole-blood-derived donor platelet or HLA-compatible apheresis platelet concentrates. Early during the course of his disease, the patient became refractory to random donor as well as HLA-matched platelet products. Nonspecific HLA antibodies were identified in his serum by 1992. No specific platelet antibodies were ever identified.
At the time of HSCT, the patient had platelet counts ranging between 3 and 8 Â 10 9 /l, associated with daily episodes of mild mucocutaneous bleeding. To eliminate HLA antibodies and improve the response to platelet transfusions before engraftment, plasmapheresis using staphylococcal protein A column IA was performed at the start of the conditioning regimen on Days À8, À7, À6, and on Day À1. We felt that the irradiation-based preparative regimen to follow would result in a rapid abrogation of IgG production. IA was performed with a COBE Spectrat cell separator fitted with a pair of Excorimt columns through which 3-4.5 volumes of the patient's plasma were passed during each procedure. The conditioning regimen consisted of total body irradiation (12 Gy) on Days À7, À6, and À5, etoposide (60 mg/kg/day) on Day À4, cyclophosphamide (50 mg/kg) on Days À3 and À2, and ATG on Days À2, À1, þ 1 and þ 2. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A and methotrexate. The patient received a matched unrelated bone marrow graft of 2.5 Â 10 8 nucleated cells/kg. Neutrophil recovery (ANC 40.5 Â 10 9 /l) occurred on Day þ 18 and platelet engraftment (first of 3 consecutive days with platelets 420 Â 10 9 /l without transfusion support) was documented on Day þ 20.
Evolution of the daily platelet count and of the 24-h corrected count increments (CCI) during the transplant period is depicted in Figure 1 . We observed a significant increase in the 24-h CCI on Days À8 to À6 and on Days 0 and þ 1, corresponding to days when IA was performed. CCI returned to values of p2 Â 10 9 /l during the days when no IA was performed. The IA procedure was well tolerated without significant side effects. Currently, the patient is alive and well 5 years following transplant, with full donor chimerism and normal blood counts.
Prior to the availability of platelet transfusions, hemorrhage was the most common cause of death among patients with marrow failure. 8 It is common practice to use prophylactic platelet transfusions for patients undergoing HSCT, although the superiority of this strategy over therapeutic platelet transfusions remains controversial. RPT greatly limits the efficacy of platelet transfusion in the prevention and treatment of serious bleeding episodes. The management of RPT due to HLA antibodies involves transfusion of HLA-matched platelet concentrates. 4 However, a lack of response to HLA-matched platelets is reported to occur in about 30% of refractory patients. The use of plasmapheresis combined with staphylococcal protein A column IA has been previously reported in the management of patients refractory to platelet transfusions outside the setting of HSCT. The first successful case was a 17-year-old patient with refractory acute myelogenous leukemia and nasal aspergillosis. 6 The patient had proven platelet-specific antibodies prior to IA, which disappeared after the second treatment. In that study, the most significant change noted in four participants was a drop in IgG of almost 37% following a 2-L plasma treatment using multiple adsorption columns. The second case was reported in a study on 10 patients. 7 A 58-year-old female with severe aplastic anemia who had RPT showed a sustained improvement in her response to platelet transfusions. In both studies, the exact nature of the platelet antibodies was not described. More recently, 10 cases were treated with a median of 5 (1-14) protein A column procedures. 5 Eight of the 10 patients had proven antibodies (six anti-HLA and two anti-HLA and anti-platelet antibodies). Six patients had a sustained increase in their platelet counts, including three patients with a statistically significant decrease in the number of platelet transfusions. Among patients who responded to therapy, five had detectable antibodies, the concentration of which decreased by 65-95% after therapy, compared to one of three unresponsive patients with detectable levels of antibodies, who experienced a similar decrease in antibody levels. From these studies, it appears that protein A column therapy can efficiently remove circulating IgGs, including those involved in RPT, with rapid clinical response.
In our case report, the aim of protein A column therapy was to improve the response to prophylactic platelet transfusions during the conditioning regimen and subsequent period of aplasia with the hope of avoiding serious bleeding complications prior to platelet engraftment. To our knowledge, this is the first report of the use of protein A column IA as part of the conditioning regimen for HSCT for patients with RPT. HSCT with myeloablative conditioning regimens involves significant risk of gastrointestinal or pulmonary hemorrhage. Although it is not possible to prove that the patient would have fared differently without the protein A column therapy, this case suggests that the removal of HLA antibodies using IA may have played a role in his favorable outcome. 
